1stOncology™: Cancer Intelligence Service – Page 758 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Piston Bio Receives Endorsement from Leading Oncologists for its Tumor Antigen-Inducing Therapeutic

On July 15, 2025 Piston Bio LLC, a biotechnology company developing both small molecules and biologics for the treatment of cancer, reported that its scientific advisors have endorsed the potential of its next-generation therapeutic designed to induce tumor surface antigens and prevent immune escape (Press release, Piston Bio, JUL 15, 2025, View Source [SID1234656348]). The endorsement follows a scientific advisory board meeting convened last month to review nonclinical data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Meeting attendees were Antoni Ribas, MD, PhD, Professor of Medicine and Director, Tumor Immunology, UCLA; Scott Antonia, MD, PhD, Professor of Medicine and Director, Cancer Institute, Duke University; Adil Daud, MD, Professor of Medicine and Director, Melanoma Clinical Research, UCSF; and Matthew Zibelman, MD, Associate Professor of Hematology/Oncology and Director of Genitourinary Clinical Research, Fox Chase Cancer Center.

"There remains significant unmet need in oncology for therapies that enhance tumor immunogenicity and improve immune recognition," said Dr. Ribas. "The nonclinical data for Piston Bio’s agent are compelling – demonstrating robust induction of tumor surface antigens and consistent antitumor activity in vivo. These findings support advancement into clinical trials, particularly given the novel mechanism and the potential for a favorable safety profile. Piston Bio’s accelerated development strategy is designed to bring innovation to patients quickly and efficiently."

"We are honored to receive the endorsement of leading oncology experts," said Walter Hong, MD, Founder and CEO of Piston Bio. "Immune escape is a key driver of relapse and resistance – tumor cells that can’t be seen can’t be eliminated. Our molecule addresses this unmet need by enhancing tumor visibility to the immune system. With a unique mechanism of action and promising nonclinical data, we are advancing rapidly toward clinical development."

Gain Therapeutics Announces Proposed Public Offering

On July 15, 2025 Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, reported that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering (Press release, Gain Therapeutics, JUL 15, 2025, View Source [SID1234654421]). Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease, and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Newbridge Securities Corporation is acting as the sole book-running manager for the proposed offering.

The securities described above will be offered pursuant to a shelf registration statement on Form S-3 (File No. 333-265061), which was previously filed with the Securities and Exchange Commission ("SEC") and became effective on June 1, 2022. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov, copies of which may be obtained, when available, for free by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, FL 33432, by email at [email protected] or by telephone at (877) 447-9625.

The offering will be made only by means of a prospectus. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

On July 15, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported the pricing of a best-efforts public offering of 12,000,000 units (Press release, BriaCell Therapeutics, JUL 15, 2025, View Source [SID1234654406]). Each unit consists of one common share (or pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and offering expenses. Each Warrant is immediately exercisable, and entitles the holder to purchase one common share at an exercise price of $1.50 per share and will expire five years from the date of issuance. The common shares (or Pre-Funded Warrants) and Warrants can only be purchased together in the offering but will be issued separately.

The offering is expected to close on July 16, 2025, subject to satisfaction of customary closing conditions. No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the securities in connection with the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

ThinkEquity is acting as the sole placement agent for the offering.

A registration statement on Form S-1 (File No. 333-288562) relating to the securities was filed with the Securities and Exchange Commission ("SEC") and became effective on July 15, 2025. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41 st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at View Source

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

On July 15, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612 ) in metastatic breast cancer (Press release, BriaCell Therapeutics, JUL 15, 2025, View Source [SID1234654405]).

BriaCell’s Phase 3 study now has 69 active clinical sites across 15 states, including Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.

"We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell’s Phase 2 study," stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. "We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families."

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus immune check point inhibitor (CPI) versus physician’s choice in advanced metastatic breast cancer (Bria-ABC).

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen . The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612.

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

On July 15, 2025 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, reported that the Company’s Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings (Press release, Tvardi Therapeutics, JUL 15, 2025, View Source [SID1234654398]).

The webcast of the fireside chat will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 60 days following the conference.